tion, neutropenia and metaphyseal dysplasia) (1) . A history of metabolic muscle disorders or early infant death may suggest Pearson bone marrow pancreas syndrome (a mitochondrial DNA disorder characterized by exocrine pancreatic dysfunction and sideroblastic anemia) (2, 3) .
Thus, assessment of exocrine pancreatic function is made easier by a thorough appreciation of the constellation of signs, both pancreatic and extrapancreatic, for various pancreatic disease. The following examples illustrate this point. in Shwachman syndrome quantification of pancreatic function is often difficult and requires invasive and expensive direct pancreatic function testing. Demonstration of a fatty pancreas on ultrasound (4,5) (bright echoes) or a radiolucent pancreas on computed tomography (CT) scan (4, 5) , characteristic hematological abnormalities, disordered neutrophil chemotaxis (6) and metaphysical dysplasia help to seal the diagnosis. Clinical characterization of other pancreatic disorders, such as Johanson-Blizzard syndrome (exocrine pancreatic dysfunction, hypoplastic alae nasi and sensorineural deafness) (7) and Pearson bone marrow pancreas syndrome, may obviate the need for invasive tests. Patients with Johanson-Blizzard syndrome have a characteristic facial appearance with hypoplastic alae nasi, and approximately 75% have sensorineural deafness due to the Mondini malformation which can be detected by CT scans of the petrous temporal bone (8) . Pearson bone marrow pancreas syndrome is characterized by sideroblastic anemia and variable suppression of other hematopoietic elements. Ring sideroblasts on bone marrow aspiration strongly suggest this diagnosis (2) .
The purpose of this review is to explore novel means of diagnosing pancreatic disease, which include pancreatic function testing, organ imaging and, more recently, molecular biology techniques. Most of the potentially novel techniques involve organ imaging or molecular biology.
PANCREATIC FUNCTION TESTING
There are three categories of exocrine pancreatic function tests (Table 1) : direct tests, which analyze the output of fluid, electrolytes and enzymes from the stimulated pancreas; indirect tests, which detect the consequences of pancreatic maldigestion of normal food substrates or synthetic substrates; and blood tests, which measure circulating pancreatic enzymes or hormones. Considerable ingenuity has resulted in these tests but the ideal pancreatic function pancreatic test remains the 'holy grail' of pancreatology.
Only direct tests delineate pancreatic function in patients with impaired pancreatic function but sufficient pancreatic enzyme output to maintain normal digestion. The only conditions in which these tests are diagnostic are isolate enzyme deficiencies, including congenital trypsinogen deficiency, congenital pancreatic lipase deficiency and colipase deficiency (9) (10) (11) . Disproportionate reduction of fluid and bicarbonate and chloride ion output in biliopancreatic secretions is highly suggestive of cystic fibrosis (12, 13) , but direct tests are hardly the method of choice for diagnosis. The secretin cholecystokinin pancreatic stimulation test may be useful in the occasional patient with unknown genotype and an equivocal sweat chloride. However, this test is not widely available and often impractical. It is also invasive, complex and time-consuming; due to a lack of standardization each centre needs to validate the test in their patient population to obtain a normal range.
There is a profusion of indirect pancreatic tests. These tests will usually detect only patients with steatorrhea, and most tests are no more useful than the original indirect pancreatic function test, the three-to five-day fecal fat collection. Many indirect tests are not specific for pancreatic disease and will detect malabsorption or malassimilation of nutrients secondary to intestinal or biliary tract disease. Tests that rely on pancreatic specific enzymes, such as cholesterol esterase, ie, the fluorescein dilaurate test (14) and the 13 C cholesteryl octanoate (15) test, partially overcome this deficiency. None of these tests nor the blood tests allow the appending of a specific diagnosis.
ORGAN IMAGING
There have been considerable advances in imaging of the exocrine pancreas. Organ imaging modes are outlined in Table 1 . Only newer modalities are discussed below.
Endoscopic ultrasound may have an improved ability to detect small pancreatic lesions compared with conventional ultrasonography. This ability is principally useful for tumour diagnosis, a rare problem in childhood. This modality can be useful for identifying tumours such as gastrinoma, but is probably no more useful that CT scan or magnetic resonance imaging (MRI) (16) . It has some value, however, to visualize the common bile duct and possible pancreatic ducts when endoscopic retrograde cholangiopancreatography (ERCP) is impractical (17) . Although of limited applicability, endoscopic evidence of duct dilation following intravenous secretin has been suggested as a diagnostic test for chronic pancreatitis (18) . Very few pediatric gastroenterology units have access to an endoscopic ultrasound.
CT is a useful modality for assessing pancreatic disease. The following disorders may have characteristic or suggestive findings on CT: annular pancreas, cystic fibrosis, Shwachman syndrome, hereditary pancreatitis, Von Hippel Lindau syndrome, pancreatic pseudocyst, pancreaticoblastoma, insulinoma and VIPoma (19) . However, most of these disor- ders will also have characteristic appearances on conventional ultrasound and MRI scan. It is not a particularly useful modality for assessing pancreatic fibrosis. Helicospiral CT scanning, which consists of continuous image acquisition, can speed up scan time and allows construction of three-dimensional images (20) . Lesional enhancement techniques and selective attenuation of surrounding tissues make this a particularly useful technique with which to look at tumours and blood vessels. If available, this technique is superior to conventional CT scan.
MRI is now considered a very good technique for imaging the pancreas. Early MRI scans had considerable problems with abdominal imaging because of the effects of movement on the signal:noise ratios. This resulted in inadequate delineation of the bowel, especially if fluid were present (21) . Movement artefact can be reduced or eliminated by a variety of techniques, including breath-holding, fast low angle shot, fat suppressed spin-echo and echoplanar imaging (22, 23) . Intravenous gadopentetate dimeglumine may be used to enhance lesions (22) . A variety of agents, including carbon dioxide, ferrous ammonium citrate, paramagnetic iron oxide and kaopectate, have been used as bowel contrast. These agents will be supplanted by oral gadolinium preparations. Excellent images are now obtained with both T 1 and T 2 weighted images. T 2 images can be used to generate MRI cholangiograms (24) and may visualize pancreatic ducts. This technique may be useful if ERCP is difficult. It will not, however, differentiate between obstruction and a tight stenosis.
Position emission tomography (PET), which is used primary as an investigational tool for amino acid handicaps (25, 26) , has also been used infrequently as a pancreatic imaging modality. The exocrine pancreas has a high propensity for amino acid uptake. Labelling amino acids with an unstable position emitting isotope ( 11 C or 13 N) allows a dynamic assessment of pancreatic function. This imaging modality may be useful for tumour assessment, particularly small hormone secreting tumours. Specificity may be improved by assessing uptake of 18 F-deoxyglucose (27) . However, it is extremely expensive, and very few pediatric centres have access to a PET scanner.
Somatostatin receptor imaging relies on a number of hormone secreting tumours that have an increased expression of somatostatin receptors. Following intravenous administration, a somatostatin analogue labelled with either 123 I or 111 In can be detected using single photon emission computerized tomography. Other hormones may be similarly labelled. This method has proven useful for imaging gastrinomas in adults (28, 29) .
Radioimmunolocalization involves labelling antibodies to cell surface markers (30) . Although most markers are not particularly specific to the pancreas, this technique has been used experimentally for tumour detection.
Digital subtraction has improved angiography by reducing the amount of contrast required and improving venous phase images. Angiography, however, is invasive and seldom needed in children. MRI and helicospiral CT scanning frequently provide adequate vascular images for diagnostic purposes.
ERCP remains the method of choice for visualizing the pancreaticobiliary tree. ERCP can be successfully performed in small infants (31) . Most pediatric units use the services of a skilled adult gastroenterologist. Endoscopic ultrasound and MRI cholangiography may be useful when ERCP is impractical.
MOLECULAR DIAGNOSIS
The diagnosis of pancreatic disease using molecular methods is an emerging science. Currently only cystic fibrosis and Pearson bone marrow pancreas syndrome can be confidently diagnosed by molecular techniques. There are more than 600 known mutations of the cystic fibrosis gene (32) . Most clinical laboratories only screen for five to seven of the most common mutations which, depending upon the ethnic background of the population, will establish the diagnosis in approximately 50% to 80% of patients. If further screening is required, material is sent to a reference laboratory. Pearson bone marrow pancreas syndrome, which is due to a large mitochondrial deletion (33) , may be amenable to molecular diagnosis. The mitochondrial genome is completely defined and should be detectable in virtually all patients by careful use of mitochondrial probes. However, patients may display heteroplasty; consequently the deletion may be present in some tissues and absent in others. Evaluation of two tissues, eg, white cells and fibroblasts or liver tissue, may help to circumvent this problem. Occasionally mitochondrial disease may be due to a defect in mitochondrial proteins expressed in genomic DNA; in these circumstances diagnosis may not be possible (33) .
The genes for colipase, trypsinogen and lipase have been provisionally assigned to 6p 21.1-pter, 7q 22-qter and 10q 24-q26, respectively (34) (35) (36) . The precise gene location and sequence have not been elucidated. cDNAs for each of the proteins have been identified. Indeed, the cDNA for human lipase has been inserted into a transformed human gallbladder epithelial line in vitro (37) . However, in the absence of precise gene location and mutation-specific probes, current mutation detection techniques do not allow disease diagnosis. However, if the protein's amino acid sequence is known, it should be possible to design a series of overlapping primers and use polymerase chain reaction amplification and direct sequencing to identify mutations in these rare disorders.
The gene and gene product have not been identified in Shwachman syndrome, Johanson-Blizzard syndrome and hereditary pancreatitis. In conditions such as Shwachman syndrome, which displays diverse pathology involving a large number of tissues, evidence of chromosome microdeletion can be sought using fluorescent in situ hybridization. Azzara et al (38) suggested that a cytoskeletal protein defect is responsible for the neutrophil chemotaxis defect in Shwachman syndrome. If the gene product can be identified, it may be possible to identify a cDNA and localize the chromosomal disorder. Alternatively, searching a gene database may allow these steps to be bypassed. SUMMARY Spectacular technical advances in organ imaging have allowed improved visualization of the pancreas. These techniques may have a limited applicability in pediatric pancreatic disease. Molecular biology has considerable potential in pancreatic disease but only cystic fibrosis and Pearson bone marrow pancreas syndrome can be diagnosed by these means. None of the advances in pancreatic diagnosis can substitute for clinical acumen.
